Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|13|35|3545-3558

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.35, 2007-12, pp. : 3545-3558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy

By  

Current Molecular Pharmacology, Vol. 2, Iss. 3, 2009-11 ,pp. : 263-284

Bentham Science Publishers

Access to resources Recommend Favorite

Interleukin (IL)-13 PE38QQR shows promise in the treatment of recurrent malignant glioma

By  

Inpharma, Vol. 1, Iss. 1415, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

By  

Current Molecular Pharmacology, Vol. 3, Iss. 1, 2010-01 ,pp. : 37-52

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic Therapy

By  

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 27-37

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for malignant glioma

By Mason Warren P  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 81-94

Informa Healthcare

Access to resources Recommend Favorite